Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Tetagam P pre-filled syringes

Marketed by Dexa Medica

Product packaging may vary from one country to another.

Ingredients in every ml

Tetanus Immunoglobulin 250 IU

Each package contains

1 syringe of 1 ml

Other details

Dosage formSyringe; pre-filled
Flavour None

W.H.O. classification

ATC Level 1 J - Antiinfectives for systemic use
ATC Level 2 J06 - Immune Sera and Immunoglobulins
ATC Level 3 J06B - Immunoglobulins



SAFE IF PRESCRIBEDThis item is safe for use during pregnancy.


SAFE IF PRESCRIBEDThis item is safe for use during lactation.


CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.


SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Available in


Dosage information

250 IU combinations with 0.5 ml of absorbed tetanus vaccine at contralateral sites of the body unless the risk is through to be extremely high. The dose may be increased to 500 IU in case of:
– Infected wounds where surgically appropriate treatment cannot be achieved within 24 hours
– Deep or contaminated wounds with tissue damage and reduced oxygen supply; as well as foreign-body injury (e.g., bites, stings or shots)
– Extensive burns, congelations
– Tissue necrosis
– Septicemic abortion
In case of extensive burns it is advisable to administer a second injection of 250 IU Tetagam at 3-4 weeks interval if the patient is immunosuppressed or if active immunization with tetanus vaccine is contraindicated.
Children and Adults are to receive the same dose

Single doses of 3000 to 6000 IU (in combination with other appropriate clinical procedures). Regarding frequency, interval of injection and duration of therapy repeated doses depend on the clinical picture.


Postexposure prophylaxis
immediate prophylaxis after tetanus prone injuries in patients
– Not adequately vaccinated
– Whose immunisation status is not known with certainty
– With severe deficiency in antibody production.

Therapy of clinically manifest tetanus
Tetanus immunoglobulin should always be administered in conjunction with an active tetanus vaccination unless there are contraindications or confirmation of adequate vaccination.